The use of these drugs has [been shown](https://diabetesjournals.org/care/article/46/2/384/147888/GLP-1-Receptor-Agonists-and-the-Risk-of-Thyroid) to drastically increase the risk of medullary thyroid cancer and all other forms of thyroid malignancies.
Those kinds of cancers aren’t very common in the general population. If someone shows they have this kind of cancer, it can be treated but it is a huge risk factor for recurrence. Adding that increased risk to the increased risk caused by the drug is usually not worth it, especially since there are alternatives to GLP-1 drugs for most people.
Latest Answers